Polymorphism G-308A in the promoter of the tumor necrosis factor-α gene and its association with the risk of venous thromboembolism

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 4, 2012, Pages 316-319

  Horakova, Kristyna ^a   Chylkova, Alicja ^a   Kolorz, Michal ^a   Bartosova, Ladislava ^a   Pechacek, Vaclav ^b   Starostka, David ^c   Wroblova, Katerina ^a  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^b Vascular Unit   (Czech Republic)

^c NSP Havirov ^*  (Czech Republic)

Author keywords

deep venous thrombosis; G 308A; gene polymorphism; PCR REA; tumor necrosis factor

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; FACTOR V; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84861097745     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283527506     Document Type: Article

References (22)

1. Krejsek J, Kopecky O. Klinickáimunologie [Clinical immunology (in Czech.)]. Hradec Králové: Nucleus HK; 2004.
2. Hajeer AH, Hutchinson IV. TNF-α gene polymorphism: clinical and biological implications. Microsc Res Tech 2000;50:216-228.
3. Ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000;28(9 Suppl):9-11.
4. Egorina EM, Sovershaev MA, Hansen JB. The role of tissue factor in systemic inflammatory response syndrome. Blood Coagul Fibrinolysis 2011;22:451-456.
5. Van Gorp ECM, Suharti C, ten Cate H, Dolmans WM, Van der Meer JW, ten Cate JW, Brandjes DP. Review: infectious diseases and coagulation disorders. J Infect Dis 1999;180:176-186.
6. Bevilasqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Nati Acad Sci 1986;83:4533-4537.
7. Parry GCN, Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol 1995;15:612-621.
8. Karmann K, Min W, Fanslow WC, Pober JS. Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1. JEM 1996;184:173-182.
9. Kambas K, Markiewski MM, Pneumatikos IA, et al. C5a and TNF-(up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J Immunol 2008;180:7368-7375.
10. Lentz SR, Tsiang M, Sadler E. Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood 1991;77:542-550.
11. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002;3:729-735.
12. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001;109:369-384.
13. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007;27:167-169.
14. Napoleone E, Di Santo A, Lorenzet R. Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. Blood 1997;89:541-549.
15. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation systé m. Cardiovasc Res 2003;60:26-39.
16. Liu HL, Lin YW, Jing W, Sun H, Gong ZC, Hu PC, et al. Impact of genetic polymorphisms of leptin and TNF-(on rosiglitazone response in Chinese patients with type 2 diabetes. Eur J Clin Pharmacol 2008;64:663-671.
17. Joseph L, Fink LM, Hauer-Jensen M. Cytokines in coagulation and trombosis: a preclinical review. Blood Coagul Fibrinolysis 2002;13:105-116.
18. Van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJ, Eerenberg AJ, et al. Elimination of interleukin-6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994;179:1253-1259.
19. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis - A systematic review of clinical studies. Schattauer GmbH 2005;94:362-365.
20. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2004;2:619-622.
21. Pieroni F, Lourenco DM, Morelli VM, Maffei FH, Zaqo MA, Franco RF. Cytokine gene variants and venous thrombotic risk in the BRATROS (BRAZILIAN THROMBOSIS STUDY). Thromb Res 2007;120:221-229.
22. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-1173.